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Abstract
Objective: Despite improving healthcare, the gap in mortality between people with serious mental illness (SMI) and general
population persists, especially for younger age groups. The electronic database from a large and comprehensive secondary
mental healthcare provider in London was utilized to assess the impact of SMI diagnoses on life expectancy at birth.
Method: People who were diagnosed with SMI (schizophrenia, schizoaffective disorder, bipolar disorder), substance use
disorder, and depressive episode/disorder before the end of 2009 and under active review by the South London and
Maudsley NHS Foundation Trust (SLAM) in southeast London during 2007–09 comprised the sample, retrieved by the SLAM
Case Register Interactive Search (CRIS) system. We estimated life expectancy at birth for people with SMI and each
diagnosis, from national mortality returns between 2007–09, using a life table method.
Results: A total of 31,719 eligible people, aged 15 years or older, with SMI were analyzed. Among them, 1,370 died during
2007–09. Compared to national figures, all disorders were associated with substantially lower life expectancy: 8.0 to 14.6 life
years lost for men and 9.8 to 17.5 life years lost for women. Highest reductions were found for men with schizophrenia (14.6
years lost) and women with schizoaffective disorders (17.5 years lost).
Conclusion: The impact of serious mental illness on life expectancy is marked and generally higher than similarly calculated
impacts of well-recognised adverse exposures such as smoking, diabetes and obesity. Strategies to identify and prevent
causes of premature death are urgently required.
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Introduction
Concerns about premature mortality among people with mental
disorders have been increasing [1–6]. Higher general and specific
causes of mortality in all or specific age groups have been identified
for people with serious mental illnesses (SMI, which might include
schizophrenia, schizoaffective disorder, bipolar disorder, and
depressive psychosis) in a range of settings [1,2,7–11], although
most report relative risks or rates of mortality rather than life
expectancy – which is arguably a more important index for shaping
policy since it takes premature mortality into account and has been
widely used for other risk exposures such as smoking, diabetes,
obesity, ethnicity and socioeconomic status [12–17]. Of the few
studies to measure this outcome, clients with SMI from public
mental health agencies in eight US states from 1997 to 2000 were
found to have lower life expectancies of 13 to more than 30 years
compared to the general population (depending on the year and
state) [2], and a loss of 8.8 life years (14.1 years for men and 5.7
years for women) was estimated in a comparison between people
treated for SMI and the general population in Massachusetts, US
[1]. A Swedish study using a nationwide hospital discharge registry
reported substantial gaps in life expectancy at age 30 for main
mental disorder categories compared to the general population,
particularly for functional psychosis other than schizophrenia /
affective psychosis (15.9 years lost), substance abuse (15.6 years lost),
and organic psychosis (14.8 years lost) among men and organic
psychosis (22.6 years lost), mental retardation (14.7 years lost), and
substance abuse (18.8 years lost) among women [18]. Preliminary
strategies for preventing premature deaths among people with SMI
have been suggested, emphasizing the management of suicide risk
and physical illness, minimum polypharmacy, and improvement of
accessibility to physical health care [19].
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of benefit on life expectancy in people with SMI [1,20,21], and
further research is urgently required [22]. We reported excess
mortality for people with diagnoses of SMI, as well as for
depressive and substance use disorders, drawing on data from the
South London and Maudsley NHS Foundation Trust Biomedical
Research Centre (SLAM BRC) Case Register, which covers
comprehensive secondary mental healthcare provision to a large
geographically defined community, by standardized mortality
ratios (SMRs) [23]. Nonetheless, equal weighting is used for each
age group in the calculation of SMRs, which is insufficient for
highlighting the impact of premature mortality among younger
age groups in the study cohort.
Methods
Ethics Statement
The study was approved as an anonymized dataset for
secondary analysis by the Oxfordshire Research Ethics Committee
C (reference 08/H0606/71).
Study Setting
Under the National Health Service (NHS) system in the UK,
there is universal state provision of healthcare, and mental health
Trusts have a close to 100% monopoly for service provision to
defined geographic catchment areas. The South London and
Maudsley NHS Foundation Trust (SLAM) is Europe’s largest
provider of secondary mental healthcare, serving four boroughs in
southeast London (urban and suburban areas) with a geographic
catchment of approximately 1.2 million residents and provision of
all aspects of secondary mental healthcare to all age groups
including inpatient, community, general hospital liaison and
forensic services. Since 2006, fully electronic clinical records have
been implemented in all SLAM services. The Case Register
Interactive Search (CRIS) system supported by the NIHR
Specialist Biomedical Research Centre for Mental Health, was
developed in 2008 to allow searching and retrieval of anonymized
full records for over 165,000 cases currently represented in the
system [24].
Mortality Detection
Detailed methods describing how the cohort of SLAM patients
with serious mental illness were identified for this study are
described elsewhere [23]. In brief, routine mortality identification
is performed on a monthly basis by SLAM through the linkage of
all NHS numbers (unique identifiers) on the case records
database (including both active and inactive cases) to nationwide
tracing provided by the NHS Care Records Service. All-cause
mortality was investigated over a three-year period from Jan 1,
2007 to Dec 31, 2009. Mental disorder diagnoses are assigned
routinely by SLAM clinical staff using the International
Classification of Diseases (ICD) coding system. Service users
who contacted SLAM before the end of 2009 (i.e. referral,
discharge, or case note entry) and received at least one diagnosis
of SMI (schizophrenia (ICD10 - F20), schizoaffective disorders
(F25), and bipolar affective disorder (F31)), substance use disorder
(F10 to F19), depressive episode (F32), or recurrent depressive
disorder (F33) prior to 2010 were included in the cohort. Five-
year age groups (0–4, 5–9, … 85–89, and 90+ years old) were
defined according to age calculated at the mid-point of the
follow-up period (i.e. Jul 1
st, 2008). For each diagnosis, the size of
population in 5-year age groups and counts of deaths in the same
age groups were obtained by gender.
Statistical Method
Life expectancy at birth is a demographic index which is a
feature of overall mortality emphasizing the impact of deaths
occurring in younger age groups. It is estimated from the age-
specific mortality of a specific cohort over a given period of time
using the life table method and is calculated from the accumulated
person-years contributed by the entire cohort divided by the total
population number at birth [25]. Methodological recommenda-
tions from the UK Office for National Statistics (ONS) have been
published [26], based on which a series of reports on life
expectancy at birth for sub-national areas of the United Kingdom
were prepared. Using Microsoft Excel, the results for the SLAM
cohorts were calculated using Chiang’s method of abridged life
tables in 5-year groups, which has been recommended for its
application to relatively small populations allowing standard errors
to be estimated [27]. In practice, since those under 15 years of age
would be unlikely to receive an SMI diagnosis, we used the UK
mortality rates for the under 15 year age groups in substitution
[28]. We then combined this with the mortality associated with
specific mental disorders. The differences in life expectancy at
birth between diagnostic groups and those for the UK population
in 2006–08 [29] were also calculated by gender. Multiple
diagnostic coding was rare during the period of interest. However,
disorder groups were analysed separately so that people with more
than one disorder coding in the surveillance period would appear
in the output for each disorder.
Results
A total of 38,066 people were identified using CRIS with a
primary diagnosis of schizophrenia, schizoaffective disorder,
bipolar affective disorder, substance use disorder, depressive
episode, or recurrent depressive disorder, recorded before the
end of 2009. Among them, 5,902 subjects were not receiving
active care from SLAM services at any point during the
surveillance period and were thus excluded from analyses in order
to increase the generalisability to other secondary mental
healthcare samples (i.e. so that the findings could be taken as
pertaining to a clearly defined sample). Those younger than 15
years old at the mid-point of 2008 or with a missing date of birth
were also excluded (n=445). Therefore, a total of 31,719 cases of
interest with 1,370 deaths were identified in the study period. Of
the sample, 1,680 (5.3%) had two diagnoses of interest before the
end of 2009, 121 (0.4%) had three diagnoses and six (0.02%) had
four diagnoses. The most common combinations of diagnoses
applied on different occasions in the same individual were
schizophrenia and schizoaffective disorders (n=421), followed by
substance use disorders and depressive disorders (n=352).
In the analyzed sample, 54.0% were male, and the mean (SD)
ages were 43.1 (14.7) years in men and 45.1 (18.0) years in women.
Cell sizes and crude mortality risks are displayed in Table 1.
Three-year mortality rates increased substantially by age groups in
both genders, and were higher for men in all age groups. Mortality
was highest in men with depression and women with schizophre-
nia. Mortality by age group and diagnosis was further displayed in
Figure 1.
Table 2 summarized the calculated life expectancies at birth by
gender for specific diagnoses and their differences from national
norms. Life expectancies at birth for people with mental disorders
ranged from 62.8 (schizophrenia) to 69.4 (schizoaffective disorders)
years in men, and from 64.1 (schizoaffective disorders) to 74.4
(depressive disorders) years in women. All the life expectancies at
birth for specific mental disorders were significantly different
between genders based on their 95% confidence intervals. Wide
Mental Disorder and Life Expectancy
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schizoaffective disorders. Specifically, men with schizophrenia had
14.6 years reduced life expectancy compared to a reduction of 9.8
years for women; meanwhile, women with schizoaffective
disorders had 17.5 years reduced life expectancy compared to a
reduction of 8.0 years for men.
Discussion
Using a large secondary mental healthcare database in
southeast London linked to national mortality returns, we
confirmed substantially shortened life expectancies at birth for
all serious mental disorder groups investigated compared to
national norms. Largest reductions were found for men with
schizophrenia, women with schizoaffective disorders, and both
men and women with substance use disorders. In previous
analyses of these cohorts, raised standardised mortality ratios
(SMRs) had been described [23], although the picture was less
dramatic because SMRs reflect less well the impact of premature
mortality at earlier life stages. In a US study conducted by the
Massachusetts Department of Mental Health from 1989 to 1994,
service users with SMI were found to have lost 8.8 years of
potential life (14.1 years for men and 5.7 for women) on average
compared to the general population, a stronger impact for men
and weaker impact for women compared to findings from our
sample. However, SMI was not specifically defined in the
Massachusetts study other than stating ‘‘evidence of serious
dysfunction’’ as an inclusion criterion [1], which might explain
the discrepancy. A Swedish analysis of national discharges from
1978–82 reported more complex data on life expectations at
given ages. For the lowest age described (30 years), subsequent life
expectancy associated with schizophrenia was 7.9 years lower in
men and 9.5 years lower in women [18] – i.e. similar to the
finding for women in our sample but less strong for men. Further
international research is clearly required to compare the potential
impacts of SMI on life expectancy in different settings since this
may provide clues as to systems of care which may help to
maximise this.
Mortality in SMI is recognised to be raised and underlying
causes may be multiple. As well as our own findings, any
psychiatric diagnosis was associated with a 65% higher than
expected total mortality in a case register study in a British
primary care cohort [30]. In the same setting, a three-fold elevated
mortality was found for coronary heart disease in young adults
with SMI, and a more than two-fold increased mortality of stroke
in all age groups [8]. Long-term antipsychotic use and adverse
lifestyle choices (e.g. obesity, smoking, poor diet, illicit drug use,
and physical inactivity) are implicated in increased risk of
cardiovascular events in these populations [3,19,20,22,31–33]
and clearly need higher levels of consideration in order to improve
health and survival, as well as the better-known risks of suicide and
violent deaths. Because the causal pathways between mental
disorder and premature mortality are multiple, and because life
years lost as an outcome measures not only the effect of an
exposure on risk of mortality but also its differential effect across
the age range, it is difficult to interpret with certainty the gender
variation in findings – i.e. the strongest effects of schizophrenia in
men and schizoaffective disorder in women. Clearly the two
disorders overlap substantially at a genetic and biological level. It is
possible that the impact of co-occurring affective disorder is
stronger in women due to specific biological or social vulnerability.
However, against this, there was no difference in the impact of
bipolar disorder between men and women and the impact of
depressive episode/disorder was stronger in men. Alternative
explanations may lie in the clinical practice of assigning diagnoses
and gender differences here – for example, if there was preferential
inclusion in women of severe personality disorders with transient
psychotic episodes within this diagnostic group. Further research is
clearly required to clarify this issue.
Life expectancy is a commonly used indicator for how longevity
may be impaired by specific long-term exposures (e.g. smoking,
obesity, ethnicity, and socioeconomic status) or chronic states of ill-
health or risk (e.g. diabetes mellitus) [12,13,15–17,34], and
provides an alternative platform to discriminate the influences of
different exposures for the purpose of highlighting premature
mortality at younger ages in potentially vulnerable groups [25]. It
Table 1. Mortality, demographic characteristics and serious mental illness diagnosis of SLAM in the period of 2007–09 (N=31,719;
death=1,370)‘.
Variable Number (number of deaths, %mortality)
Male (n=17,113) Female (n=14,579)
Age groups
15–29 3,202 (25, 0.78) 3,091 (11, 0.36)
30–44 7,410 (159, 2.15) 5,224 (65, 1.24)
45–59 4,351 (165, 3.79) 3,403 (95, 2.79)
60–74 1,473 (188, 12.76) 1,535 (127, 8.27)
75–89 621 (193, 31.08) 1,185 (258, 21.77)
90+ 56 (27, 48.21) 141 (57, 40.43)
SMI diagnosis
Schizophrenia (F20) 4,426 (196, 4.43) 2,592 (126, 4.86)
Schizoaffective disorders (F25) 652 (16, 2.45) 660 (28, 4.24)
Bipolar affective disorder (F31) 1,126 (43, 3.82) 1,573 (65, 4.13)
Substance use disorders (F10–F19) 7,654 (254, 3.32) 3,268 (94, 2.88)
Depressive episode and recurrent depressive disorder (F32–F33) 4,264 (284, 6.66) 7,417 (336, 4.53)
‘Number of missing gender information=27.
doi:10.1371/journal.pone.0019590.t001
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Diagnosis Male Female
Life Expectancy (95% CI,
number of deaths)
Difference from
male UK population*
Life Expectancy
(95% CI, number
of deaths)
Difference from female
UK population*
Any Serious Mental Illness‘ 64.5 (63.3–65.6, n=243) 212.9 69.9 (68.7–71.0, n=203) 211.8
Schizophrenia (F20)‘ 62.8 (61.6–64.10, n=196) 214.6 71.9 (71.0–72.8, n=126) 29.8
Schizoaffective disorder (F25)‘ 69.4 (68.3–70.5, n=16) 28.0 64.1 (60.9–67.2, n=28) 217.5
Bipolar affective disorder (F31)‘ 67.3 (66.1–68.5, n=43) 210.1 70.4 (69.5–71.4, n=65) 211.2
Substance use disorders (F10–F19)‘ 63.9 (62.7–65.0, n=254) 213.6 66.9 (65.5–68.3, n=94) 214.8
Depressive episode and recurrent
depressive disorder (F32–F33)‘
66.8 (65.6–67.9, n=284) 210.6 74.4 (73.5–75.3, n=336) 27.2
*Life expectancy at birth 2006–08 in UK: Male=77.4 years; Female=81.6 years [27].
‘Significant difference between genders.
doi:10.1371/journal.pone.0019590.t002
Figure 1. Annual mortality risk (%) by age groups and diagnoses of mental illness, compared to England and Wales population in
2008.
doi:10.1371/journal.pone.0019590.g001
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complementary to more common studies using measures of effect,
such as SMR statistics. As a measure, life expectancy analyses
provide an important means of communicating impact on survival
to policy makers and lay audiences. This approach also allows the
impact of different exposures to be compared in a way which
cannot be inferred from SMR outputs. As a case in point,
considering the impact of other well-recognised exposures and
comparing these with the potential impact of SMI, in a Japanese
study of life expectancy from age 40, smoking was the most
important predictor of six lifestyle related exposures (smoking,
alcohol consumption, walking duration, sleep duration, consump-
tion of green leafy vegetables, and obesity), current smoking being
associated with around four to five life years lost for both genders
[12,13]. Considering 2005 life expectancy levels in the USA (75.1
years for men and 80.3 years for women), current and previous
smoking was associated with 2.5 years lower life expectancy for
men and 1.8 years lower life expectancy for women [17]. For
British doctors born in 1900–1930 and followed up for fifty years,
continued smoking was associated with around 10 years life lost,
compared to lifelong non-smokers [16], and in New Zealand
Census records in 1996, the gap in life expectancy between current
and never smokers was 7.6 years in men and 6.7 for women [15].
Diabetes was reported to reduce life expectancy at age 15 by 1.3
years for men and 2.0 years for women in Canada [14], and a
BMI of 40–45 kg/m
2 was associated with a 10 year reduction of
life expectancy at age 35 compared to a BMI 22.5–25 kg/m
2 [35].
The potential impact of having a serious mental illness (or a
substance use disorder or a depressive episode requiring secondary
care contact) on life expectancy is therefore at least comparable
and at worse substantially higher than effects of individual well-
recognised exposures, although clearly the mechanisms through
which mental disorders are associated with premature mortality
will include the effects of these individual risk factors (for example,
smoking behaviour, risk of diabetes, etc.) as well as other factors
(such as risk of suicide or accidents and direct effects of mental
distress on cardiovascular risk). Excess mortality associated with
mental disorders has been demonstrated to be predominantly due
to ‘natural’ causes [3,5,30,31,36–38], although mental health
service provision is often focused on preventing more rare
outcomes of suicide and violent death [39–41]. If improving
overall survival is to be considered as an alternative priority, much
more efforts are clearly required to address the challenges of
improving general health in people with mental disorders through
medical services, socioeconomic support, and physical health
promotion strategies [19].
Strengths of the study described include the large sample size
and nationwide coverage of mortality, as well as the context of
complete electronic clinical records. Potential limitations include
the secondary healthcare setting; this should present no problem
for high penetrance disorders, such as schizophrenia and bipolar
disorder, where most cases will have received secondary care
input. However, findings for substance use disorders and
depressive disorders should be viewed with circumspection since
those appearing on a secondary care register are likely to be an
unrepresentative (and probably more severe) subset of community
cases. Ultimately, the findings for life expectancy should be taken
as referring to people with these mental disorders who had made
contact with secondary mental health services within the given
time period and are not necessarily applicable to all cases in a
given community. Diagnostic categories overlapped, but only a
minority (5.7%) of people had received more than one mental
disorder diagnosis during the surveillance period. Nevertheless,
comorbidity between SMI and substance use disorders should not
be assumed to be captured as the source data reflected primary
diagnoses rather than co-occurrence. Also we did not attempt to
capture co-occurring or changing diagnoses which present
potentially complex issues for analysis in a secondary care sample
and which we felt were beyond the scope of this initial report.
Although SLAM is a major academic as well as clinical centre,
mental disorders on the Case Register are likely to be broadly
generalizable to other urban settings in the UK (the SLAM
catchment covers a range of residence areas from inner city to
suburban settings but does not include any rural areas). Life
expectancy comparisons of regional data to national norms may
be problematic. However, in a sensitivity analysis of SMR data,
the use of London comparators did not meaningfully change
findings [23]. Also, from administrative data, life expectancy at
birth for population of the four catchment area boroughs in 2007–
09 (ranging from 76.3–79.5 years for males and 81.1–82.9 years
for females), were not substantially different to national estimates
[42].
Our results demonstrate the substantial impact of serious mental
illness on life expectancy and highlight importance of developing
strategies to prevent premature mortality among people with SMI
and other major mental disorders. Although the prevention of
suicides and violent deaths are likely to be an important
component, other causes of excess mortality should not be
ignored, including cardiovascular diseases, cancer, and diabetes
[3,4,7,8,22,31]. Physical health risk assessments and assertive
intervention by primary and secondary medical services have been
proposed and have resulted in improvements [20,43]. Continued
monitoring of mortality trends in people with mental disorders will
be required to evaluate the impact of policy changes as they occur.
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